These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34092612)

  • 1. The predictive potential of Neuronatin for neoadjuvant chemotherapy of breast cancer.
    Pieper W; Ignatov A; Kalinski T; Haybaeck J; Czapiewski P; Nass N
    Cancer Biomark; 2021; 32(2):161-173. PubMed ID: 34092612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
    Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
    Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High neuronatin (NNAT) expression is associated with poor outcome in breast cancer.
    Nass N; Walter S; Jechorek D; Weissenborn C; Ignatov A; Haybaeck J; Sel S; Kalinski T
    Virchows Arch; 2017 Jul; 471(1):23-30. PubMed ID: 28540450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
    Villegas SL; Darb-Esfahani S; von Minckwitz G; Huober J; Weber K; Marmé F; Furlanetto J; Schem C; Pfitzner BM; Lederer B; Engels K; Kümmel S; Müller V; Mehta K; Denkert C; Loibl S
    Breast Cancer Res Treat; 2018 Feb; 168(1):179-187. PubMed ID: 29177689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.
    Caparica R; Richard F; Brandão M; Awada A; Sotiriou C; de Azambuja E
    Clin Breast Cancer; 2020 Jun; 20(3):262-273.e7. PubMed ID: 32229175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study.
    Woo J; Oh SJ; Song JY; Chae BJ; Choi JE; Lee J; Park HK; ; Lim W
    BMC Cancer; 2021 May; 21(1):647. PubMed ID: 34059020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
    Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
    Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can the Neutrophil to Lymphocyte Ratio Predict Complete Pathologic Response to Neoadjuvant Breast Cancer Treatment? A Systematic Review and Meta-analysis.
    Cullinane C; Creavin B; O'Leary DP; O'Sullivan MJ; Kelly L; Redmond HP; Corrigan MA
    Clin Breast Cancer; 2020 Dec; 20(6):e675-e681. PubMed ID: 32653471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early progression of breast cancer during neoadjuvant chemotherapy may predict poorer prognoses.
    Myller S; Ipatti P; Jääskeläinen A; Haapasaari KM; Jukkola A; Karihtala P
    Acta Oncol; 2020 Sep; 59(9):1036-1042. PubMed ID: 32394761
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer.
    Zhong W; Yang Y; Zhang A; Lin W; Liang G; Ling Y; Zhong J; Yong J; Liu Z; Tian Z; Lin Q; Luo Q; Li Y; Gong C
    Breast Cancer; 2020 Nov; 27(6):1147-1157. PubMed ID: 32780321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Different Phenotypes of Locally Advanced Breast Cancer During Neoadjuvant Systemic Treatment.
    Muñoz-Montaño W; Cabrera-Galeana P; Alvarado-Miranda A; Villarreal-Garza C; Mohar A; Olvera A; Bargallo-Rocha E; Lara-Medina F; Arrieta O
    Clin Breast Cancer; 2020 Aug; 20(4):307-316.e1. PubMed ID: 32305297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy.
    Nogi H; Uchida K; Mimoto R; Kamio M; Shioya H; Toriumi Y; Suzuki M; Nagasaki E; Kobayashi T; Takeyama H
    Clin Breast Cancer; 2017 Dec; 17(8):644-649. PubMed ID: 28601382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 Acts as a Promising Immune Marker to Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
    Du Q; Che J; Jiang X; Li L; Luo X; Li Q
    Clin Breast Cancer; 2020 Feb; 20(1):e99-e111. PubMed ID: 31521537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response and Prognosis of Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in ER
    Hayashi N; Yagata H; Tsugawa K; Kajiura Y; Yoshida A; Takei J; Yamauchi H; Nakamura S
    Clin Breast Cancer; 2020 Dec; 20(6):462-468. PubMed ID: 33046356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome.
    Plasterer C; Tsaih SW; Peck AR; Chervoneva I; O'Meara C; Sun Y; Lemke A; Murphy D; Smith J; Ran S; Kovatich AJ; Hooke JA; Shriver CD; Hu H; Mitchell EP; Bergom C; Joshi A; Auer P; Prokop J; Rui H; Flister MJ
    Breast Cancer Res Treat; 2019 Aug; 177(1):77-91. PubMed ID: 31165373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
    Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients.
    Zemni I; Ghalleb M; Jbir I; Slimane M; Ben Hassouna J; Ben Dhieb T; Bouzaiene H; Rahal K
    World J Surg Oncol; 2017 Nov; 15(1):206. PubMed ID: 29169398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer.
    Spanheimer PM; Carr JC; Thomas A; Sugg SL; Scott-Conner CE; Liao J; Weigel RJ
    Am J Surg; 2013 Jul; 206(1):2-7. PubMed ID: 23375759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.